Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.58 |
| ▸ | EGFR | P00533 | 11/20 | 0.48 |
| ▸ | BRAF | P15056 | 3/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 2/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1373577 | 0.94 | ENPP1 (0.58) | ENPP1EGFRBRAFABCG2KDR | |
| SCHEMBL29359187 | 0.82 | ENPP1 (0.81) | ENPP1EGFRLCKKDRFLT1 | |
| SCHEMBL364049 | 0.82 | ENPP1 (0.81) | ENPP1EGFRLCKKDRFLT1 | |
| SCHEMBL24393053 | 0.82 | EGFR (0.48) | EGFRBRAFABCG2CSF1R | |
| SCHEMBL21664408 | 0.82 | EGFR (0.48) | EGFRBRAFABCG2LCKKDR | |
| SCHEMBL3528775 | 0.81 | ENPP1 (0.70) | ENPP1EGFRBRAFABCG2KDR | |
| Hydrochloric Acid SCHEMBL3526531 | 0.80 | ENPP1 (0.79) | ENPP1EGFRLCKKDRFLT1 | |
| SCHEMBL24008957 | 0.80 | ENPP1 (0.63) | ENPP1EGFRKDRFLT1 | |
| SCHEMBL24391772 | 0.79 | EGFR (0.46) | ENPP1EGFRBRAFABCG2KDR | |
| SCHEMBL16636797 | 0.79 | PDE4A (0.40) | ENPP1EGFRBRAFKDRRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11752153-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230172932-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-06-08 | — | — | US | disclosed |
| US-11524010-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210369713-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | SOUTHERN RESEARCH INSTITUTE (US) | 2021-12-02 | — | — | US | disclosed |
| US-20200038402-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038402-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | TXN, TXN2, TXNRD1 | ENPP1 2457/4885EGFR 4829/4885BRAF 1473/4885 |
| US-11524010-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | TXN, TXNL1, TXN2 | ENPP1 2704/4885EGFR 4824/4885BRAF 1044/4885 |
| US-20210369713-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | TXN, TXNL1, TXN2 | ENPP1 2704/4885EGFR 4824/4885BRAF 1044/4885 |
| US-20230172932-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | TXN, TXNL1, TXN2 | ENPP1 2704/4885EGFR 4824/4885BRAF 1044/4885 |
| US-11752153-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | TXN, TXNL1, TXN2 | ENPP1 2704/4885EGFR 4824/4885BRAF 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.